Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies-Reference-Cited by-同舟云学术

Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies

Published:2017-08-24 Issue:12 Volume:20 Page:1244-1251
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Bonafede Machaon¹,Richhariya Akshara²,Cai Qian¹,Josephson Neil C.²,McMorrow Donna¹,Garfin Phillip M.³,Perales Miguel-Angel³

Affiliation:

1. Truven Health Analytics, an IBM company, Cambridge, MA, USA;

2. Seattle Genetics, Inc., Bothell, WA, USA;

3. Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical College, New York, NY, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1364648

Reference17 articles.

1. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer

2. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation

3. D'Souza A, Zhu X. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2016. Available at: http://www.cibmtr.org [Last accessed 14 September 2016.

4. Costs of Hematopoietic Cell Transplantation: Comparison of Umbilical Cord Blood and Matched Related Donor Transplantation and the Impact of Posttransplant Complications

5. Prevalence of Hematopoietic Cell Transplant Survivors in the United States

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthcare Resource Utilization and Cost Associated with Allogeneic Hematopoietic Stem Cell Transplantation: A Scoping Review;Transplantation and Cellular Therapy;2024-05

2. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia;Leukemia & Lymphoma;2024-04-22

3. Healthcare costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective;Blood Advances;2023-12-06

4. Hospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis from a Pivotal Phase 3 Clinical Trial;Transplantation and Cellular Therapy;2023-12

5. Financial burden and recommended multilevel solutions among caregivers of pediatric hematopoietic stem cell transplant recipients;Pediatric Blood & Cancer;2023-09-30